Navigation Links
Agency Takes Adverse Decision to Biopure's Product Registration in South Africa
Date:10/28/2008

CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it had received a notice from the Medicines Control Council (MCC) of South Africa indicating its decision to discontinue the registration of Hemopure [hemoglobin glutamer-250 (bovine)], Biopure's oxygen therapeutic for human use. The decision is subject to appeal. Biopure intends to appeal the decision promptly and expects to continue to market the product while the appeal is pending. The appeal is estimated to take a year to resolve.

The MCC decision comes after a letter sent to the South Africa Minister of Health on May 22, 2008, asking that the then ongoing clinical trials of Hemopure in South Africa be brought to a halt because of the "evidence against blood substitutes." The letter was sent by Public Citizen and signed by three of the authors of a so-called meta-analysis of hemoglobin-based blood substitutes published online April 28, 2008, by the Journal of the American Medical Association. The letter to the Minister of Health characterized the results of, and enclosed a copy of, the article.

Biopure expects that an appeal before a hearing body, to be chosen by the Minister of Health, but subject to challenge by Biopure, will succeed. Biopure has done all required reporting on Hemopure's usage since its approval for marketing in South Africa in 2001, including monitoring and reporting to the MCC on use of the product in the first 80 patients treated. Thereafter, a South African doctor consulting for Biopure collected patient data on more than 200 patients, published an article on that clinical experience and submitted the information to the MCC. Since Hemopure was approved for marketing in South Africa, there have been no serious adverse events required to be reported to the MCC from clinical use of the product in approximately 500 patients. Consequently, an appeal should establish that there is not a basis for this action. Biopure expects that local experts will strongly support its appeal.

Upon learning that the negative communication had been sent to the Minister of Health of South Africa and to each other country where Biopure had ongoing trials, Biopure demanded a retraction and sent an objection to the National Institutes of Health (NIH) regarding Charles Natanson of the NIH signing the Public Citizen letters using his NIH title. Earlier this month, Biopure brought an action against Natanson alleging various torts, including defamation, trade libel and intentional interference with prospective business advantage, seeking injunctive relief and damages. Biopure is announcing the filing of that litigation separately.

The MCC also ordered the halt of clinical trials in South Africa, but Biopure had already stopped patient enrollment in its trials there earlier this year, for reasons of slow enrollment and cost containment.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The Company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that any appeal will be successful. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on September 15, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Relations PR & Marketing Named Agency of Record for Advanced Ultrasound Services
2. Credit Counseling Agency Helps Consumers Live Healthier While Becoming Financially Fit
3. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
4. Physicians Health Choice Hires Blue Clover as Agency of Record
5. Medical Advertising Agency Healthcare Success Strategies Wins Two Gold Awards
6. DSM Pharmaceutical Products Announces the Appointment of Thats Nice LLC as Agency of Record for Marketing
7. Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group
8. Hockert Joins Wausau Signature Agency
9. Community Leaders to Protest Los Angeles Community Redevelopment Agency
10. French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
11. Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: